BioCryst: Orladeyo's Expansion Is Just Getting Started

Group 1 - The biotech sector has experienced significant volatility, with investors often focusing on hyped plays rather than long-term winners [1] - BioCryst Pharmaceuticals is highlighted as a strong player in the rare disease market that has not yet received adequate market recognition [1] - The approach to investment in high-growth companies involves a combination of fundamental analysis and future trend prediction, emphasizing the potential of innovation for substantial returns [1]